Literature DB >> 25617530

Differential effects of oxycodone, hydrocodone, and morphine on the responses of D2/D3 dopamine receptors.

Michael A Emery1, M L Shawn Bates1, Paul J Wellman1, Shoshana Eitan2.   

Abstract

Oxycodone and hydrocodone are opioids which are widely used for pain management and are also commonly misused and abused. The exposure to opioid analgesics has been associated with altered responses of D2-like dopamine receptors (D2DRs). Our recent results suggest that various opioids will differentially modulate the responses of D2DRs. The D2DRs are known to be involved in the pathology of addiction and other mental illnesses, indicating the need to improve our understanding of the effects of opioid analgesics on the responses of the D2DRs. Thus, in this study, we first established equianalgesic oral doses of oxycodone, hydrocodone, and morphine using the tail withdrawal assay. Then, mice were orally administered (gavage) with the various opioids or saline once daily for 6 days. Twenty-four hours later, the mice were tested for their locomotor response to quinpirole, a D2/D3 dopamine receptor agonist. Mice pretreated with oxycodone showed significantly greater locomotor supersensitivity to quinpirole than did morphine-pretreated mice, while hydrocodone-pretreated mice showed sensitivity in between that of mice treated with morphine and oxycodone. This finding suggests that various opioids differentially modulate the responses of D2DRs. It provides further evidence supporting of the notion that various opioids carry differential risks to the dopamine reward system.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Abuse; Addiction; Analgesics; Opioid; Pain management

Mesh:

Substances:

Year:  2015        PMID: 25617530     DOI: 10.1016/j.bbr.2015.01.023

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  5 in total

1.  Oxycodone physical dependence and its oral self-administration in C57BL/6J mice.

Authors:  Rachel M Enga; Asti Jackson; M Imad Damaj; Patrick M Beardsley
Journal:  Eur J Pharmacol       Date:  2016-07-05       Impact factor: 4.432

2.  RGS9-2 Modulates Responses to Oxycodone in Pain-Free and Chronic Pain States.

Authors:  Sevasti Gaspari; Valeria Cogliani; Lefteris Manouras; Ethan M Anderson; Vasiliki Mitsi; Kleopatra Avrampou; Fiona B Carr; Venetia Zachariou
Journal:  Neuropsychopharmacology       Date:  2017-01-11       Impact factor: 7.853

Review 3.  Endogenous Opioids at the Intersection of Opioid Addiction, Pain, and Depression: The Search for a Precision Medicine Approach.

Authors:  Michael A Emery; Huda Akil
Journal:  Annu Rev Neurosci       Date:  2020-02-28       Impact factor: 12.449

4.  Preclinical and Clinical Pharmacology of Hydrocodone for Chronic Pain: A Mini Review.

Authors:  Luigi Cardia; Gioacchino Calapai; Domenico Quattrone; Cristina Mondello; Vincenzo Arcoraci; Fabrizio Calapai; Carmen Mannucci; Epifanio Mondello
Journal:  Front Pharmacol       Date:  2018-10-01       Impact factor: 5.810

Review 5.  Oxycodone in the Opioid Epidemic: High 'Liking', 'Wanting', and Abuse Liability.

Authors:  Cherkaouia Kibaly; Jacob A Alderete; Steven H Liu; Hazem S Nasef; Ping-Yee Law; Christopher J Evans; Catherine M Cahill
Journal:  Cell Mol Neurobiol       Date:  2020-11-27       Impact factor: 4.231

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.